Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Chimeric Therapeutics Ltd. ( (AU:CHM) ) just unveiled an announcement.
Chimeric Therapeutics shareholders have endorsed all resolutions put to an Extraordinary General Meeting held on 17 April 2026, with each motion carried by poll. The approved items include ratification of prior share issues, authorisation of new share and option issuances linked to a placement and adviser arrangements, and consent for a share consolidation.
Investors also backed the issue of warrants and convertible notes to a noteholder as part of a capital-raising strategy, signalling strong support for Chimeric’s funding plans. The breadth of approvals provides the company with expanded flexibility to restructure its capital base and secure additional financing, which may strengthen its balance sheet and support ongoing therapeutic development programs.
More about Chimeric Therapeutics Ltd.
Chimeric Therapeutics Limited is an Australian biotechnology company listed on the ASX that focuses on developing cell-based therapies for cancer. The company operates in the life sciences sector, targeting oncology indications with advanced therapeutic platforms aimed at improving treatment options for patients and enhancing long-term shareholder value.
Technical Sentiment Signal: Sell
Current Market Cap: A$6.63M
Find detailed analytics on CHM stock on TipRanks’ Stock Analysis page.